



# PURPOSE

Prevention with PURPOSE

## Pregnant and Lactating People in the Lenacapavir for HIV PrEP PURPOSE Program

Moupali Das, MD, MPH

[www.purposestudies.com](http://www.purposestudies.com)

@drmoupali

CROI Symposium: State of the art research to advance PrEP in Pregnant and Lactating People

Feb 19<sup>th</sup>, 2023



We are in this until  
we end the HIV  
epidemic  
for everyone,  
everywhere



Legacy of  
making  
medicines for  
people with  
HIV



**17.6**  
million people  
treated with  
Gilead HIV  
drugs

The New York Times  
F.D.A. Advisory Panel Backs  
Preventive Use of H.I.V. Drug





**10.5**  
years since  
Truvada was  
approved for  
PrEP in the US



# Together we are breaking new ground on ways to do trials

HIV Counterfactual:  
HIV cases/100 PY



Aisha Fayyaz

Collaboration  
Transparency

# LEN for PrEP: Prevention with PURPOSE



Community & stakeholder collaboration

Person-Centered Design

Investigator engagement

Proof of Concept that Capsid Inhibitors Prevent SHIV in Non-Human Primates  
Robust Pharmacokinetic and Safety Database in persons with and without HIV

Phase 1 Studies

LEN Mucosal PK

 Capella Highly treatment experienced


 Calibrate Antiretroviral naïve





# PURPOSE 1 Design: Randomized Blinded Phase

LEN for PrEP in cisgender adolescent girls and young women




# F/TDF, F/TAF and LEN in PLP

- The safety of F/TDF during pregnancy and breastfeeding has been established
  - F/TDF is recommended during pregnancy and breastfeeding in South Africa<sup>1</sup>
- Currently available data on F/TAF use in pregnancy have not revealed safety concerns
  - The IMPAACT 2010 trial demonstrated better pregnancy outcomes in women with HIV receiving DTG+F/TAF compared to DTG+F/TDF or EFV/F/TDF<sup>2</sup>
  - PK studies have shown low TAF levels in breast milk and cord blood<sup>3,4</sup>
- Lenacapavir (LEN) is a novel, first-in-class, capsid inhibitor that is a twice-yearly subcutaneous injection which is approved for PWLH with multidrug resistant HIV
  - While there are no human studies of LEN in pregnancy, preclinical studies do not indicate harmful effects of LEN on fertility, pregnancy, fetal development, or postnatal development

1. Lane et al. Policy Considerations for Scaling Up Access to HIV PrEP for Adolescent Girls and Young Women in Uganda [http://www.go2itech.org/wp-content/uploads/2019/12/PrEP-Brief\\_Uganda\\_Oct2017.pdf](http://www.go2itech.org/wp-content/uploads/2019/12/PrEP-Brief_Uganda_Oct2017.pdf);  
2. Chinula et al., CROI, 2020, Oral Abstract #130; 3. Momper JD et al. AIDS, 2018, Oral Abstract THAB0302; 4. Bojun L et al., 29th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), 2020, Abstract 1444



# Recent Conceptual Shifts For Research in Pregnancy



Regulatory authorities and experts in the field published guidance documents advocating for PLP inclusion in clinical trials of novel antiretrovirals<sup>6-9</sup>

5. The PHASES Working Group. Ending the evidence gap for pregnant women around HIV and co-infections: A call to action. 2020 July; 6. Committee on Ethics. Obstet Gynecol. 2015;126:e100-7; 7. Food and Drug Administration. Enhancing the diversity of clinical trial populations—eligibility criteria, enrollment practices, and trial designs: guidance for industry; Nov 2020; 8. Food and Drug Administration. Pregnant women: scientific and ethical considerations for inclusion in clinical trials: guidance for industry; Apr 2018; 9. WHO, IMPAACT, and CIPHER. Research for informed choices: accelerating the study of new drugs for HIV in pregnant and breastfeeding women: a call to action.



# Global Consultation to Plan for Inclusion of Pregnant and Lactating Populations in a Phase 3 PrEP Clinical Trial

Dázon Dixon Diallo,<sup>1</sup> Yvette Raphael,<sup>2</sup> Moupali Das,<sup>3</sup> Ntando Yola,<sup>4</sup> Bridget Jjuuko,<sup>5</sup> Margaret Happy,<sup>6</sup> Elizabeth Spooner,<sup>7</sup> Daya Moodley,<sup>8</sup> Jenna Yager,<sup>3</sup> Alexander Kintu,<sup>3</sup> Christoph Carter,<sup>3</sup> Priyanka Arora,<sup>3</sup> Jared Baeten,<sup>3</sup> Flavia Matovu-Kiweewa<sup>9</sup>


<sup>1</sup>SisterLove, Inc., Atlanta, Georgia, US; <sup>2</sup>APHA: Advocates for the Prevention of HIV in Africa, Johannesburg, South Africa; <sup>3</sup>Gilead Sciences, Inc., Foster City, California, US; <sup>4</sup>Desmond Tutu Health Foundation, Cape Town, South Africa; <sup>5</sup>ACTS101-Uganda, Kampala; <sup>6</sup>AQH-Uganda: Advocacy for Quality Health Uganda, Kampala; <sup>7</sup>SAMRC: South African Medical Research Council, Durban, South Africa; <sup>8</sup>CAPRISA: Centre for the AIDS Programme of Research in South Africa, Umlazi; <sup>9</sup>MU-JHU Care Ltd/MU-JHU Research Collaboration, Kampala



# PLP Inclusion and PK Sub-Studies

Stakeholder and G-CAG identified priorities, including PLP inclusion, sites experienced in caring for complex PLP, and PK in pregnancy, breast milk, and infant plasma

## Pregnancy, Breast milk, and Infant PK Sub-Studies:



Participants who become pregnant on study will be able to continue after re-consent

Compared with studies of prior HIV drugs, the pregnancy, lactation, and breast milk substudy in PURPOSE 1 will provide data on these key populations at the time of approval instead of years later

<b>Objectives</b>	<ul style="list-style-type: none"> <li>Describe maternal systemic drug concentrations during pregnancy and postpartum period</li> <li>Qualitatively assess drug concentrations in maternal breast milk and paired infants</li> </ul>
<b>Limit burden</b>	<ul style="list-style-type: none"> <li>No additional samples for maternal PK</li> <li>Breast milk and infant samples collected at 2 scheduled visits post-delivery</li> <li>Participants can opt out of breast milk and infant PK sampling</li> </ul>





# PURPOSE: First to Include PLP and Adolescents in Phase 3 Clinical Trials



Aisha Fayyaz

PHASES  
PREGNANCY + HIV/AIDS  
SEEKING EQUITABLE STUDY

## Ending the evidence gap for pregnant women around HIV & co-infections:

### A CALL TO ACTION

“Rather than justifying inclusion of pregnant people, exclusion of pregnant persons from research should be justified”

“Protect pregnant people through research instead of from research”

The PHASES Working Group  
Pregnancy and HIV/AIDS: Seeking Equitable Study

issued July 2020




Nadia Bormotova



ACCP Position Paper

## Inclusion of Adolescents With Adults in Phase 3 Clinical Trials: Overview of the Current State and a Call for Action

Mohamed-Eslam F. Mohamed, RPh, PhD<sup>1,2</sup> , Natella Rakhmanina, MD, PhD, FCP<sup>3,4</sup>, and Hazem E. Hassan, RPh, MS, PhD<sup>1</sup>

The Journal of Clinical Pharmacology  
2020, 60(5) 559–562  
© 2020, The American College of  
Clinical Pharmacology  
DOI: 10.1002/jcph.1591

WEBINAR

## A Call to Action on World AIDS Day

Research for  
Informed Choices:  
Accelerating the  
Study of New Drugs  
for HIV in Pregnancy

1 December 2021




In the PURPOSE trials, all persons assigned female at birth are supported in their reproductive choices; contraception is not required but is provided; pregnant participants may continue on study drug after re-consent. Compared to prior HIV drugs, the Pregnancy, Lactation, and Breastmilk Substudy in PURPOSE 1 and inclusion of Adolescents in both trials will provide data on these key populations at time of approval instead of years later





# PURPOSE 2 Design: Randomized Blinded Phase

LEN for PrEP in men who have sex with men, transgender women, transgender men and nonbinary people




CGMSM, cisgender men who have sex with men; GNB, gender nonbinary individuals; TGM, transgender men; SC, subcutaneous; po, oral; qd, daily; q6m, every six months; bHIV, background HIV incidence rate; RITA, recent infection testing algorithm





# PURPOSE 2 First to include transgender men and gender non-binary people in PrEP Trial

HIV prevalence in TGW: 19%



**"As a transmasculine person who has sex with cis men...my identity... is historically and consistently overlooked by the HIV establishment."**

—Max Appenroth, Cologne







Read ***No Data No More***,  
a manifesto for the priorities of trans and  
gender-diverse people in #HIVprevention R&D.  
[avac.org/no-data-no-more](https://avac.org/no-data-no-more)

Transgender people have been traditionally underrepresented in HIV research and are often disproportionately affected by HIV

PURPOSE 2 will strive to enroll 20% transgender women, and will be inclusive of transgender men and gender non-binary people who have sex with men



# Inclusion of PLP across the PURPOSE program

 <b>PURPOSE 1</b>	 <b>PURPOSE 2</b>	 <b>PURPOSE 3</b> <b>HPTN 102</b>	 <b>PURPOSE 4</b> <b>HPTN 103</b>
<p>Participants may choose whether to receive contraception.</p> <p>Participants who become pregnant while on study will be able to continue on study after reconsent.</p>	<p>Contraception required for those AFAB of childbearing potential.</p> <p>Participants who become pregnant while on study will be able to continue on study after reconsent.<sup>†</sup></p> <p><sup>†</sup> If taking testosterone, they must discontinue testosterone if continuing the pregnancy and wish to continue study drug.</p>	<p>Participants may choose whether to receive contraception.</p> <p>Participants who become pregnant while on study will be able to continue on study after reconsent.</p>	<p>Participants may choose whether to receive contraception.</p> <p>Participants who become pregnant while on study <i>may</i> be able to continue on study after reconsent.</p>

[www.purposestudies.com](http://www.purposestudies.com)



# Questions?

With sincere gratitude for all our participants, community accountability and advisory group members, trial site staff, site investigators, collaborators, and other stakeholders

We are in this until we end the HIV epidemic for everyone, everywhere

Moupali Das, MD, MPH  
Moupali.Das@gilead.com  
[www.purposestudies.com](http://www.purposestudies.com)  
@drmoupali

